Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel

Vaccine

Volumn 26, Issue 7, 2008, Pages 869-873

  Singer, Darrell E ^a   Schneerson, Rachel ^b   Bautista, Christian T ^a   Rubertone, Mark V ^c   Robbins, John B ^b   Taylor, David N ^d  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c Army Medical Surveillance Activity   (United States)

^d VaxInnate Corporation   (United States)

Author keywords

Anthrax; Bacillus anthracis; IgG; Military; Vaccine

Indexed keywords

ANTHRAX VACCINE; IMMUNOGLOBULIN G;

ADULT; ANTHRAX; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; DOSAGE SCHEDULE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; SOLDIER; UNITED STATES;

ADOLESCENT; ADULT; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MILITARY PERSONNEL; UNITED STATES; VACCINATION;

EID: 38649131301     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.085     Document Type: Article

References (25)

1. Blanchard J.C., Haywood Y., Stein B.D., Tanielian T.L., Stoto M., and Lurie N. In their own words: lessons learned from those exposed to anthrax. Am J Public Health 95 3 (2005) 489-495
2. Friedlander A.M., Pittman P.R., and Parker G.W. Anthrax vaccine: evidence for safety and efficacy against inhalation anthrax. JAMA 282 22 (1999) 2104-2106
3. The Anthrax Vaccine. Is It Safe? Does It Work? Institute of Medicine, 2002, National Academy Press. Washington, DC; 2002, pp. 6-10 and 49-50.
4. Armed Forces Epidemiological Board Recommendation Regarding Deviation from Anthrax Vaccine Policy; 1998 [Accessed June 13, 2007, at http://www.ha.osd.mil/afeb/1998/1998-11.pdf].
5. Executive Order 13139-Improving Health Protection of Military Personnel Participating in Particular Military Operations; 1999 [Accessed June 13, 2007, at http://www.archives.gov/federal-register/executive-orders/1999.html].
6. Anthrax Vaccinations to Resume; October 17, 2006 [Accessed November 26, 2007 at http://www.military.com/NewsContent/0,13319,116977,00.html?ESRC=army-a.nl].
7. Brossier F., Lévy M., Landier A., Lafaye P., and Mock M. Functional Analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun 72 11 (2004) 6313-6317
8. Lim N.K., Kim J.H., Oh M.S., Lee S., Kim S.Y., Kim K.S., et al. An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect Immun 73 10 (2005) 6547-6551
9. Price B.M., Liner A.L., Park S., Leppla S.H., Mateczun A., and Galloway D.R. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 69 7 (2001) 4509-4915
10. Turnbull P.C., Leppla S.H., Broster M.G., Quinn C.P., and Melting J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol 177 5 (1988) 293-303
11. Advisory Committee on Immunization Practices. Use of anthrax vaccine in the United States. MMWR Recomm Rep 2000; 49(RR-15):1-20.
12. Myers M.G., Beckman C.W., Vosdingh R.A., and Hankins W.A. Primary immunization with tetanus and diphtheria toxoids. Reaction rates and immunogenicity in older children and adults. JAMA 248 19 (1982) 2478-2480
13. Barr M., Glenny A.T., and Randall K.J. Diphtheria immunisation in young babies. Lancet 1 1 (1950) 6-10
14. Erdos L. The problem of interval in primary immunization consisting of several vaccinations. Z Gesamte Hyg 20 11 (1974) 784-788
15. Rubertone M.V., and Brundage J.F. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health 92 12 (2002) 1900-1904
16. Quinn C.P., Dull P.M., Semenova V., Li H., Crotty S., Taylor T.H., et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 190 7 (2004) 1228-1236
17. Ashkenazi S., Passwell J.H., Harlev E., Miron D., Dagan R., Farzan N., et al. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J Infect Dis 179 6 (1999) 1565-1568
18. Hanson J.F., Taft S.C., and Weiss A.A. Neutralizing antibodies and persistence of immunity following anthrax vaccination. Clin Vaccine Immunol 13 2 (2006) 208-213
19. Hoffmaster A.R., Hill K.K., Gee J.E., Marston C.K., De B.K., Popovic T., et al. Characterization of Bacillus cereus isolates associated with fatal pneumonias: strains are closely related to Bacillus anthracis and harbor B. anthracis virulence genes. J Clin Microbiol 44 9 (2006) 3352-3360
20. Avashia S.B., Riggins W.S., Lindley C., Hoffmaster A., Drumgoole R., Nekomoto T., et al. Fatal pneumonia among metalworkers due to inhalation exposure to Bacillus cereus containing Bacillus anthracis toxin genes. Clin Infect Dis 44 3 (2007) 414-416
21. Brachman P.S., Kauffmann A.F., and Dalldorf F.G. Industrial inhalation Anthrax. Bacteriol Rev 30 3 (1966) 646-659
22. Anthrax Vaccine Immunization Program [accessed in June 13, 2007, available at http://www.anthrax.osd.mil/vaccine/protect5.asp].
23. Lininger L.A., Cullum M.E., Lyles M.B., and Bienek D.R. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine. Vaccine 25 9 (2007) 1619-1625
24. Pittman P.R., Kim-Ahn G., Pifat D.Y., Coonan K., Gibbs P., Little S., et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20 9-10 (2002) 1412-1420
25. Pittman P.R., Norris S.L., Barrera Oro J.G., Bedwell D., Cannon T.L., and McKee Jr. K.T. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 24 17 (2006) 3654-3660